Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial).
about
Establishment and characterization of a novel murine model of pancreatic cancer cachexia.Cancer-induced muscle wasting: latest findings in prevention and treatment.Muscle wasting in heart failure : The role of nutrition.Update on Management of Cancer-Related Cachexia.Publication trends in cachexia and sarcopenia in elderly heart failure patients.The role of adipose tissue in cancer-associated cachexia.Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial.Cytomegalovirus serostatus, inflammation, and antibody response to influenza vaccination in older adults: The moderating effect of beta blockade.Highlights from the 9th Cachexia Conference.Single-nucleotide polymorphisms in cachexia-related genes: Can they optimize the treatment of cancer cachexia?ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker.Casting the net broader to confirm our imaginations: the long road to treating wasting disorders.Sex Differences in Muscle Wasting.An analysis of the types of recently published research in the field of cachexia.Deterioration of Limb Muscle Function During Acute Exacerbation of Chronic Obstructive Pulmonary Disease.Therapeutic considerations of sarcopenia in heart failure patients.Pitfalls in the measurement of muscle mass: a need for a reference standard.Muscle wasting and sarcopenia in heart failure and beyond: update 2017.Cachexia therapies - the need to take a broader look.Anti-catabolic neurohormonal blockade to improve skeletal muscle during disease.Cardiac Cachexia - A Window to the Wasting DisordersCardiac cachexia: perspectives for prevention and treatmentSkeletal muscle aging: influence of oxidative stress and physical exerciseCancer-induced muscle wasting: latest findings in prevention andPhysiological culture conditions alter myotube morphology and responses to atrophy treatments: implications for in vitro research on muscle wasting.Protein imbalance in the development of skeletal muscle wasting in tumour-bearing miceTime to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018
P2860
Q38653925-2B772280-4A98-43F0-8E22-1D3E18B56361Q38681113-5B0FCF98-BB03-4443-BDF8-65897CF8D09BQ38985792-8E787974-687E-4540-AEFE-5DF6B8FF2886Q38990581-0186F982-A8EF-4A75-AD2C-265B81D8644CQ39019268-65FCD44F-365F-4703-9432-57B23F2BFF4FQ39033683-7DA9BE6F-D9F0-4B2F-BEDC-59E22DADF74FQ40315420-E3EC7C3B-DF0E-467A-8877-A0899676DF17Q40512629-899BAD58-DC57-469E-A170-8607A6E2EA3FQ41093566-F0C6008A-E63A-40B8-BFEE-A7BCE3FF4546Q42336582-1A799BA5-6055-4B78-AD7E-B8DB8D54965FQ42398016-36086BC6-A98B-4146-BE9F-ED50EA84FFE1Q47132964-2D251A25-EEB9-456F-9791-29B3B0A929E6Q47311543-38C9BF78-41D0-43D5-8B3A-30612B82375AQ47568983-DA648B14-CDE8-45A4-A742-A726AE4C6915Q47734308-041519CC-9F26-499E-A972-37E7B8A89145Q47747144-D7CBC84F-34F2-466A-9737-703C6619EF5FQ49032117-7D6F5875-4AD4-4965-8AC6-E7002279CEE1Q49183956-FCA6EBF8-9643-43DC-BF44-B9EDA6090B1AQ49586619-7EB58E5D-36D0-4972-93A3-BED3A23EF3B9Q50092681-91834B8A-CB86-426C-A259-5DE3251023A1Q51763185-89B2805D-1877-4552-8BB8-E55F958D60CAQ55364177-EDCE794A-114F-4004-B8FD-0EE807447D5AQ57458063-634161F0-EB95-424A-89D6-0592D228A4F2Q57476138-59D97514-018F-473B-A579-3BB0841187B0
P2860
Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Espindolol for the treatment a ...... II study (the ACT-ONE trial).
@en
Espindolol for the treatment a ...... II study (the ACT-ONE trial).
@nl
type
label
Espindolol for the treatment a ...... II study (the ACT-ONE trial).
@en
Espindolol for the treatment a ...... II study (the ACT-ONE trial).
@nl
prefLabel
Espindolol for the treatment a ...... II study (the ACT-ONE trial).
@en
Espindolol for the treatment a ...... II study (the ACT-ONE trial).
@nl
P2093
P2860
P921
P356
P1476
Espindolol for the treatment a ...... II study (the ACT-ONE trial).
@en
P2093
Andrew J Stewart Coats
Gwo Fuang Ho
John Beadle
Julia Tilson
Kumar Prabhash
Richard Brown
for and on behalf of the ACT‐ONE study group
P2860
P304
P356
10.1002/JCSM.12126
P577
2016-06-01T00:00:00Z